) recently announced the launch of three type II diabetes drugs
in the US - Nesina (alogliptin), Kazano (alogliptin and metformin
hydrochloride), and Oseni (alogliptin and pioglitazone).
Nesina, Kazano and Oseni received US Food and Drug
Administration (FDA) approval in Jan 2013. These drugs are to be
used along with diet and exercise.
As per the FDA, type II diabetes affects roughly 24 million
people, forming 90% of total diabetes patients in the US. The
type II diabetes market is currently crowded with drugs like
Januvia, Bydureon. Janumet, VIctoza and IDegLira
The FDA had asked for 5 post-marketing studies for Nesina, 2
for Kazano and 1 for Oseni. Kazano carries a boxed warning for
lactic acidosis while Oseni carries a boxed warning for heart
failure associated with pioglitazone use.
Nesina was launched in Japan in the year 2010. These
three drugs are under review in the EU, where it was submitted in
the second quarter of 2012. Takeda expects EU decision in the
second half of 2013.
In 2005, Takeda acquired development and marketing rights to
all dipeptidyl peptidase IV (DPP4) inhibitors from
Furiex Pharmaceuticals, Inc.
The 2013 financial guidance provided by Takeda in May 2013
includes the effect of this launch. For 2013, Takeda expects Net
sales of 1590 billion yen and earnings per share of 120.34
Takeda carries a Zacks Rank #3 (Hold). Other companies like
Jazz Pharmaceuticals plc
Salix Pharmaceuticals Ltd.
) look more attractive with a Zacks Rank #1 (Strong Buy).
FURIEX PHARMACT (FURX): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
SALIX PHARM-LTD (SLXP): Free Stock Analysis
TAKEDA PHARMACT (TKPYY): Get Free Report
To read this article on Zacks.com click here.